Mallinckrodt Pharmaceuticals plc and Endo Inc. said Thursday they are combining as part of a stock-and-cash deal with an enterprise value of $6.7 billion that will give both companies a roughly 50 ...

Per the terms, Endo shareholders are expected to receive $80M in cash and own a 49.9% stake in the combined entity headquarters in Dublin, Ireland, while Mallinckrodt (OTCPK:MCKPF) investors will ...

Data from Phase 2 Trial VGX-001-012 of Mizagliflozin in Post Bariatric Hypoglycemia will be Presented RALEIGH, NC / ACCESS Newswire / April 15, 2025 /Vogenx, Inc., a clinical-stage developer of novel ...